We see a trend towards increasingly concentrated drug formulations due, for example, to the decreasing popularity of intravenous administration. This trend presents manufacturing challenges. In this presentation, Parviz Shamlou, Vice President of the Jefferson Institute for Bio-Processing discusses the challenges associated with high concentration and high viscosity monoclonal antibody formulations, how biopharma manages these challenges today and how the Jefferson Institute addresses these issues.
Kendal Studd, Scientific Applications Specialist at Advanced Instruments will close the session by discussing the challenges for analytical devices in testing these formulations and how advances in osmolality testing in particular are applied to help minimise the risks.
Parviz Ayazi-Shamlou, Jefferson Institute for Bioprocessing
Parviz Shamlou is the Vice President & Executive Director at Jefferson Institute for Bioprocessing (JIB) at Thomas Jefferson University (TJU). JIB is a multi-million dollar state-of-the art facility that provides cutting edge training, and research in bioprocessing. Parviz Shamlou has over 30 years a of academic and industry experience in bioprocessing, from ideation to commercial products including protein and monoclonal antibodies, cell and gene therapy and advanced vaccines.
Kendal Studd, Advanced Instruments
Kendal specializes in advancing novel osmolality applications within the biopharma industry. She is an experienced scientist with a demonstrated history of working in the biotechnology industry alongside sterilising grade filters and pharmaceuticals. She graduated from the University of Portsmouth with Distinction in a research Masters's degree looking at DNA extraction and amplification via PCR.